Table 1. Basic features of the publications included in this meta-analysis (n=15).
| Study | Year | Country | Cancer type | Patients | Reference gene | Detection method | Cut-off | HR statistics | Survival analysis | Hazard ratios(95%CI) | Follow-up (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ma, X. | 2019 | China | NSCLC | 24 | GAPDH | qRT-PCR | Mean-value | Report | OS | 3.30 (1.36–7.98) | 60 |
| Dong, Y. | 2018 | China | NSCLC | 49 | GAPDH | qRT-PCR | Mean-value | Survival curve | OS | 1.85 (0.95–3.60) | 120 |
| DFS | 2.22 (1.17–4.21) | 120 | |||||||||
| Cui, X. | 2018 | China | NSCLC | 55 | GAPDH | qRT-PCR | Mean-value | Report | OS | 2.23 (1.03–4.83) | 80 |
| Jin, B. | 2017 | China | NSCLC | 35 | GAPDH | qRT-PCR | Median | Survival curve | OS | 1.63 (0.56–4.74) | 60 |
| Zhang, J. | 2017 | China | HCC | 152 | GAPDH | qRT-PCR | NA | Report | OS | 2.25 (1.33–3.79) | 70 |
| Liu, Y. | 2018 | China | PTC | 136 | GAPDH | qRT-PCR | Median | NA | NA | NA | 60 |
| Wu, D. | 2018 | China | PTC | 92 | GAPDH | qRT-PCR | Median | Survival curve | OS | 1.89 (0.78–4.58) | 60 |
| Huang, L. | 2018 | China | CRC | 91 | GAPDH | qRT-PCR | Median | Report | OS | 2.73 (1.00–7.42) | 70 |
| Qu, C. | 2019 | China | EOC | 182 | GAPDH | qRT-PCR | Mean-value | Report | OS | 1.14 (1.07–1.21) | 60 |
| PFS | 1.120 (1.056–1.189) | 60 | |||||||||
| Kong, Q. | 2018 | China | BC | 58 | GAPDH | qRT-PCR | Median | Survival curve | OS | 1.86 (0.80–4.32) | 60 |
| Ma, Y. | 2017 | China | Glioma | 46 | GAPDH | qRT-PCR | Mean-value | Survival curve | OS | 3.81 (0.34–42.69) | 60 |
| Du, Y. | 2018 | China | ccRcc | 96 | NA | qRT-PCR | Median | NA | NA | NA | NA |
| Chen, S. | 2015 | China | GC | 106 | GAPDH | qRT-PCR | NA | Report | OS | 2.928 (1.304–6.575) | 40 |
| DFS | 2.399 (1.377–4.177) | 40 | |||||||||
| Guo, X. | 2018 | China | PA | 171 | GAPDH | qRT-PCR | Mean-value | Report | OS | 3.251 (1.177–6.362) | 60 |
| Ma, Z. | 2017 | China | PDA | 48 | GAPDH | qRT-PCR | NA | NA | NA | NA | NA |
Abbreviations: BC, breast cancer; ccRCC, clear cell renal cell carcinoma; CRC, colorectal cancer; DFS, disease-free survival; EOC, epithelial ovarian cancer; ESCC, esophageal squamous carcinoma; GC, gastric cancer; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HCC, hepatocellular carcinoma; NA, not available; No., number; NSCLC, non-small cell lung cancer; OS, overall survival; PA, pancreatic cancer; PDA, pancreatic ductal adenocarcinoma; PFS, progress-free survival; PTC, papillary thyroid carcinoma; qRT-PCR, quantitative reverse transcription-polymerase chain reaction.